Healthcare - Biotechnology - NASDAQ - US
$ 1.5884
4.5 %
$ 41.2 M
Market Cap
-4.96
P/E
CASH FLOW STATEMENT
-8.09 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
-62.4 K
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Anebulo Pharmaceuticals, Inc.
| Net Income | -8.2 M |
| Depreciation & Amortization | 258 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 759 K |
| Change in Working Capital | -799 K |
| Others | -270 K |
| Free Cash Flow | -8.09 M |
Cash Flow
Millions
| Jun-2024 | Jun-2023 | Jun-2022 | Jun-2021 | Jun-2020 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (8.2) | (11.7) | (6.8) | (30.3) | (0.2) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 0.8 | 0.9 | 0.5 | 0.2 | 0 |
| Other Operating Activities | 0.2 | 0.7 | 0.2 | 26.6 | 1.29 K |
| Change in Working Capital | (0.8) | 1.2 | 0.9 | (1.4) | 22.6 K |
| Cash From Operations | (8.1) | (9.7) | (5.4) | (4.9) | (0.2) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Other Items | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | 0 | 0 | 0 | 0 | 0 |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | (0.2) | 0.2 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 62.4 K | (0.3) | 0 | (0.8) | 0 |
| Cash From Financing Activities | 62.4 K | 6.4 | 0 | 21.8 | 3.2 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (8.2) | (3.3) | (5.4) | 17.0 | 3.0 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (8.1) | (9.7) | (5.4) | (4.9) | (0.2) |